Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
bluebird bio
bluebird bio
Activities:
Research & Development
X
LinkedIn
Trending Articles
Optimising RNA production for faster and cheaper pharmaceutical manufacturing
RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool
The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Manufacturing
Minaris to manufacture Bluebird Bio therapy for CALD
Early Cerebral Adrenoleukodystrophy is a life-threatening progressive neurodegenerative disease
Ingredients
Refined commercial production spec gets gene therapy EMA go-ahead
US-based Bluebird Bio is working with German apceth Biopharma for commercial manufacturing of its one-time thalassemia therapy that is approved in the EU, not the US
Regulatory
Apceth bullish on manufacturing deal with bluebird bio
The German CDMO will operate as commercial manufacturer in Europe for Zynteglo, bluebird bio's first gene therapy to gain regulatory approval
Manufacturing
Bluebird bio opens lentiviral vector manufacturing facility
The US company’s first facility will produce clinical and commercial supplies of gene therapy vectors, with room for expansion
Pharmaceutical
Collaboration to develop gamma delta CAR T cell product candidates
bluebird bio and Scottish immunotherapy company TC BioPharm, announced a strategic collaboration and license agreement focused on gamma delta CAR T cells
Research & Development
Lonza and Bluebird Bio announce commercial manufacturing agreement
For Lenti-D and LentiGlobin therapies for severe genetic diseases and T cell-based immunotherapies for cancer
You need to be a subscriber to read this article.
Click here
to find out more.
Research & Development
Homing in on cancer targets
Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach
Subscribe now